Last reviewed · How we verify
Sustanon 250
Sustanon 250 is an oil-based injectable testosterone blend used to treat low testosterone levels in men.
Sustanon 250 is an oil-based injectable testosterone blend used to treat low testosterone levels in men. Used for Hypogonadism, Delayed puberty.
At a glance
| Generic name | Sustanon 250 |
|---|---|
| Also known as | Testosterone |
| Sponsor | Jules Bordet Institute |
| Drug class | Anabolic steroid |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
It contains a mixture of four different testosterone esters, which are slowly released into the bloodstream over time, providing a sustained increase in testosterone levels. This helps to alleviate symptoms of low testosterone, such as fatigue, decreased libido, and osteoporosis.
Approved indications
- Hypogonadism
- Delayed puberty
Common side effects
- Acne
- Hair loss
- Elevated liver enzymes
- Mood changes
- Sleep apnea
Key clinical trials
- Body Composition Assessment in Transgender Population.
- Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism (PHASE2)
- Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life (EARLY_PHASE1)
- RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) (PHASE2)
- Pubertal Replacement In Boys Study Nebido and Testoviron Depot Treatment (NA)
- The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism (PHASE4)
- Generation of Biological Samples Positive to Testosterone for Anti-doping Control (PHASE1)
- Systemic Hormones and Muscle Protein Synthesis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sustanon 250 CI brief — competitive landscape report
- Sustanon 250 updates RSS · CI watch RSS
- Jules Bordet Institute portfolio CI